Intervention not reported
Time to treatment withdrawal ‐ stratified by seizure type ‐ Generalised seizures Range of · adults and children with newly diagnosed partial onset or generalised onset seizures
The intervention may leads to higher time to treatment withdrawal ‐ stratified by seizure type ‐… (low certainty).
1 finding from 1 review
Intervention not reported
Time to 12‐month remission ‐ stratified by seizure type ‐ Generalised seizures Range of · adults and children with newly diagnosed partial onset or generalised onset seizures
The intervention showed no clear difference in time to 12‐month remission ‐ stratified by seizure type ‐… (moderate certainty).
1 finding from 1 review
Intervention not reported
Time to 6‐month remission ‐ stratified by seizure type ‐ Generalised seizures Range of · adults and children with newly diagnosed partial onset or generalised onset seizures
The intervention showed no clear difference in time to 6‐month remission ‐ stratified by seizure type ‐ Generalised… (moderate certainty).
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Quality of life · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in any adverse event grade ≥ 3 compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in bowel fistula / perforation (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Recurrent UTI after end of therapy · children with acute pyelonephritis
Agent: Third generation cephalosporin showed no clear difference in recurrent UTI after end of therapy compared with other antibiotic (low certainty).
1 finding from 1 review
General functioning ‐ no clinically important change in general functioning · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Any intervention for KCOT (e.g. enucleation), alone or combined with an adjunctive therapy (ostectomy, cryotherapy, or Carnoy's solution) vs A different intervention (e.g. enucleation versus marsupialisation), or the same surgical intervention without the adjunctive therapy
Outcome not reported · Adults over the age of 18 with a validated diagnosis of solitary keratocystic odontogenic tumours (KCOT) arising in the jaw bones of the…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with TKI followed by TKI maintenance probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Hypertension grade ≥ 3 · newly‐diagnosed EOC
Chemotherapy with TKI followed by TKI maintenance may leads to higher hypertension grade ≥ 3 compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · platinum‐sensitive recurrent EOC
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · platinum‐sensitive recurrent EOC
Chemotherapy with TKI followed by TKI maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found